Sign In
Buy IBD
$23.82
+0.0800 (+0.337%)
At Close: Jun 23, 2026
- Data reveal WTX-921 is efficacious in a mouse colitis model, resulting in reduced tissue damage and inflammatory cytokine production -
Carlsbad, CA, May 01, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on devel
What's Going On With Treasury Rates?
12:30pm, Friday, 18'th Apr 2025
We think the Fed has time to assess the impact of tariffs, and we expect it to wait to cut rates until the data show that tariffs are impacting the real economy. So far, there are no signs of recessio
Is Inspire Corporate Bond ETF (IBD) a Strong ETF Right Now?
07:21am, Tuesday, 25'th Mar 2025
A smart beta exchange traded fund, the Inspire Corporate Bond ETF (IBD) debuted on 07/10/2017, and offers broad exposure to the Investment Grade Corporate Bond ETFs category of the market.
J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease
09:31am, Friday, 21'st Mar 2025
FDA approves J&J's Tremfya for its fourth indication and the second IBD condition.
Gold Stocks Steal The Luster In IBD Growth List; These Stocks Stand Out
11:21am, Friday, 14'th Mar 2025
Gold stock Agnico Eagle Mines has passed a buy point and outperformed the S&P 500. Other gold stocks have entered the IBD 50.
GE, IBD's Stock Of The Day, Doubles Investments In U.S. Factories
01:14pm, Thursday, 13'th Mar 2025
GE Aerospace doubling investments in U.S. factories with commercial and military jet-engine deliveries set to grow. The post GE, IBD's Stock Of The Day, Doubles Investments In U.S. Factories appeared
Spyre Therapeutics: Targeting The Future Of IBD Treatment
04:51am, Tuesday, 04'th Mar 2025
Spyre Therapeutics is emerging as a key player in inflammatory bowel disease, with a focus on pathway-specific monoclonal antibodies for superior disease control. The company has a healthy balance she
Nvidia Earnings Preview: Blackwell, DeepSeek And Big Expectations | Earnings Cheat Sheet | IBD
07:00am, Friday, 21'st Feb 2025
IBD's Alissa Coram and Ed Carson preview key upcoming earnings reports from Nvidia, Axon and Cava. Check out our daily newsletter!
Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data
01:33pm, Tuesday, 28'th Jan 2025
Piper Sandler analyst David Amsellem reiterated the Overweight rating on Teva Pharmaceutical Industries Limited TEVA with a price forecast of $30.
Is Inspire Corporate Bond ETF (IBD) a Strong ETF Right Now?
07:21am, Tuesday, 21'st Jan 2025
A smart beta exchange traded fund, the Inspire Corporate Bond ETF (IBD) debuted on 07/10/2017, and offers broad exposure to the Investment Grade Corporate Bond ETFs category of the market.
IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva
02:57pm, Wednesday, 08'th Jan 2025
Catalyst struck a deal Wednesday with Teva that will prevent the generic drugmaker from knocking off Firdapse until 2035. The post IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva
Carpenter Technology Stock Receives IBD Stock Rating Upgrade
04:24pm, Thursday, 02'nd Jan 2025
Carpenter Technology saw its IBD SmartSelect Composite Rating jump to 96 Thursday, up from 94 the day before. The post Carpenter Technology Stock Receives IBD Stock Rating Upgrade appeared first on In
Binah Capital Recognized Among Industry Leaders in the Financial Planning's Top Deal Makers List “Top IBD Moves and M&A Deals of 2024”
01:04pm, Thursday, 02'nd Jan 2025
Recognition Underscores Binah's Transformative Impact on the Financial Services Industry Recognition Underscores Binah's Transformative Impact on the Financial Services Industry
IBD Sector Leader Breaks Out On First China Policy Shift In 14 Years
04:11pm, Thursday, 26'th Dec 2024
Sector leader Atour Lifestyle has been riding the China stimulus wave as it hovers near a buy point and all-time high. The post IBD Sector Leader Breaks Out On First China Policy Shift In 14 Years app
